Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis

Next Previous
Trial Profile

A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Intermediate uveitis; Panuveitis; Posterior uveitis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms VISUAL III
  • Sponsors Abbott Healthcare; AbbVie

Most Recent Events

  • 24 Oct 2018 Interim results data cut off (31 oct 2016) of 0 to 78 weeks assessing efficacy of adalimumab by immunosuppressant use in non-infectious intermediate, posterior, or panuveitis patients, presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
  • 16 Jun 2018 Long-term safety and efficacy results (n=371; interim data cut off 31 Oct 2016) presented at the 19th Annual Congress of the European League Against Rheumatism.
  • 16 Jun 2018 Results (n=371) evaluating long term safety and efficacy presented at the 19th Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top